Overview
Our bioluminescent IVISbrite™ tumor cell lines (formerly Bioware™ Brite) are stably transfected with the firefly luciferase reporter gene from Luciola Italica (Red-F-luc) that allows you to visualize the growth of the cells in vivo. Once the cell lines are injected into an appropriate mouse model, subsequent expression of the optimized Red-F-luc luciferase gene allows you to monitor early tumor development, monitor tumor growth and metastases even in deep tissue, quantify tumor burden in a whole animal model, and follow therapeutic responses non-invasively. Revvity currently offers tumor cell lines covering a range of cancer models including breast, colorectal, prostate, lung, and lymphoma.
IVISbrite tumor cell lines contain the brighter, red-shifted Red-F-luc reporter gene and are bright enough to measure tumor growth in deep tissues, well before the tumors are palpable, allowing you to start collecting data at time points and tissue depths not possible with traditional micrometer measurements.
Also available are dual-labeled cell lines expressing Red-F-luc luciferase and GFP green fluorescent protein (allowing you to monitor tumor growth in vivo with luciferase and ex vivo (in analyses such as immunohistochemistry) with the fluorescent protein. Revvity currently offers dual labeled cell lines in breast and prostate cancer models.
Figure 1: 1 million HT1080-Red-F-Luc cells were injected subcutaneously into the dorsal region near the thigh of female nu/nu mouse. Tumor growth was monitored for luciferase expression using the Revvity IVIS® Spectrum optical imaging system at various time points. Mice were imaged 10 minutes post i.p. injection of luciferin at 150 mg/kg at various time points. The image above shows tumor growth from a representative mouse.
Product selection table and culturing information
Blood cancer cell lines
| Cell line | Reporter type | Tissue | Applications | Culture media | Antibiotic selection – not required for culturing | Product number |
|---|---|---|---|---|---|---|
| K-562-Red-F-luc | Firefly luciferase (luminescence) | Human: chronic myelogenous leukemia (CML) | • Orthotopic tumor model (Intracerebral implantation) | RPMI 1640 (ATCC Catalog No. 30-2001) with 10% Heat inactivated FBS | Puromycin at 2 µg/mL | BW124735 |
Brain oncology
| Cell line | Reporter type | Tissue | Applications | Culture media | Antibiotic selection – not required for culturing | Product number |
|---|---|---|---|---|---|---|
| GL261-Red-F-luc | Firefly luciferase (luminescence) | Mouse: Glioma | Monitor mouse glioma xenograft non-invasively in real time | DMEM (ATCC cat#: 30-2002) with 10% FBS. Selection Marker: 100 ug/ml G418 | Puromycin at 2 µg/mL | BW134246 |
| U-87 MG-Red-F-luc | Firefly luciferase (luminescence) | Human: glioblastoma; Brain | • Subcutaneous tumor models • Orthotopic tumor model (Intracerebral implantation) |
Eagle's Minimum Essential Medium (ATCC Catalog No. 30-2003) with 10% Heat inactivated FBS; | Puromycin at 2 µg/mL | BW124577 |
Breast cancer cell lines
| Cell line | Reporter type | Tissue | Applications | Culture media | Antibiotic selection – not required for culturing | Product number |
|---|---|---|---|---|---|---|
| MCF-7-Red-F-luc | Firefly luciferase (luminescence) | Human: adenocarcinoma, mammary gland | • Mammary fat pad orthotopic model • Mammary fat pad with lung metastasis |
Eagle’s MEM ATCC (Cat. No. 30-2003) with 10% Fetal Bovine Serum (FBS) | Puromycin at 2 µg/mL | BW119262 |
| 4T1-Red-F-luc | Firefly luciferase (luminescence) | Mouse: mammary gland; adenocarcinoma | • Mammary fat pad orthotopic tumor model • Subcutaneous tumor models |
RPMI 1640 ATCC Catalog Number 30-2001 with 10% heat inactivated FBS | Puromycin at 5 µg/mL | BW124087 |
| 4T1-Red-F-luc-GFP | Dual: Luciferase (luminescence) and GFP (fluorescence) | Mouse: mammary gland; adenocarcinoma | • Mammary fat pad orthotopic tumor models • Subcutaneous tumor models • Ex vivo cell isolation using fluorescent activated cell sorter (FACS) • Post genomic analyses of isolated tumor cells. • Immunohistochemistry detection of GFP positive cells |
RPMI 1640 ATCC (Catalog Number 30-2001) with 10% heat inactivated FBS | There is NO antibiotic selection for this cell line. | BW128090 |
Colorectal oncology
| Cell line | Reporter type | Tissue | Applications | Culture media | Antibiotic selection – not required for culturing | Product number |
|---|---|---|---|---|---|---|
| Colo205-Red-F-luc | Firefly luciferase (luminescence) | Human: adenocarcinoma; colorectal | • Subcutaneous tumor models • Subcutaneous tumor models with metastasis (SCID-bg mice) |
RPMI 1640 (ATCC Catalog No. 30-2001) with 10% Heat inactivated FBS | Puromycin at 2 µg/mL | BW124317 |
| HCT 116-Red-F-luc | Firefly luciferase (luminescence) | Human: adenocarcinoma; colorectal | • Subcutaneous tumor models • Subcutaneous tumor models with metastasis (SCID-bg mice) |
McCoy’s 5a Medium Modified, (ATCC catalog no. 30-2007) with 10% Heat inactivated FBS | Puromycin at 2 µg/mL | BW124318 |
| HT-29-Red-F-luc | Firefly luciferase (luminescence) | Human: adenocarcinoma; colorectal | • Subcutaneous tumor models • Subcutaneous tumor models with metastasis (SCID-bg mice) Note: Not recommended for colon orthotopic injection or implantation. |
McCoy’s 5A, 1X (ATCC Catalog No. 10-050-CV) with 10% Heat inactivated FBS | Puromycin at 2 µg/mL | BW124353 |
Fibrosarcoma
| Cell line | Reporter type | Tissue | Applications | Culture media | Antibiotic selection – not required for culturing | Product number |
|---|---|---|---|---|---|---|
| HT1080-Red-F-luc | Firefly luciferase (luminescence) | Human: Fibrosarcoma; adenocarcinoma | • Testing immunomodulation of drugs in vivo • In vivo subcutaneous tumor models |
Eagle’s MEM (ATCC Cat. No.30-2003) with 10% heat inactivated FBS | Puromycin at 2 µg/mL | BW128092 |
Liver oncology
| Cell line | Reporter type | Tissue | Applications | Culture media | Antibiotic selection – not required for culturing | Product number |
|---|---|---|---|---|---|---|
| HepG2-Red-F-luc | Firefly luciferase (luminescence) | Human: Hepatocellular carcinoma | • In vivo liver metastasis • Subcutaneous models |
Eagle’s MEM (ATCC Cat. No.30-2003) with 10% FBS. Selection Marker: 2 mg/ml Puromycin | Puromycin at 2 µg/mL | BW134280 |
Lung cancer
| Cell line | Reporter type | Tissue | Applications | Culture media | Antibiotic selection – not required for culturing | Product number |
|---|---|---|---|---|---|---|
| A549-Red-F-luc | Firefly luciferase (luminescence) | Human: carcinoma, lung | • Subcutaneous tumor models • Experimental metastasis models (intravenous in SCID-bg mice) |
RPMI-1640 (Mediatech Cat. No. 10-040-CV) + 10% FBS | Puromycin at 2 µg/mL | BW119266 |
| LL/2-Red-F-luc | Firefly luciferase (luminescence) | Mouse: carcinoma, lung | • Subcutaneous tumor models • Subcutaneous tumor models with metastasis (SCID-bg mice, successful at slower rate of growth for C57BL/6 and C57BL/6-albino mice) • Experimental metastasis models (intravenous) Note: Recommended mouse strains for in vivo imaging: SCID-beige (CR) and C57BL/6-albino (JAX). |
Dulbecco's MEM (ATCC Cat. No. 30-2002) + 10% FBS | Puromycin at 2 µg/mL | BW119267 |
| NCI-h560-Red-F-luc | Firefly luciferase (luminescence) | Human: adenocarcinoma; Lung | • Subcutaneous tumor models • Subcutaneous tumor models with metastasis (SCID-bg mice) • Orthotopic lung tumor models |
RPMI 1640 ATCC Cat. No. 30-2001 with 10% heat- inactivated FBS | Puromycin at 2 µg/mL | BW124316 |
Melanoma
| Cell line | Reporter type | Tissue | Applications | Culture media | Antibiotic selection – not required for culturing | Product number and tech sheet |
|---|---|---|---|---|---|---|
| B16-F10-Red-F-luc | Firefly luciferase (luminescence) | Mouse: Melanoma | • Subcutaneous tumor models • Experimental metastasis models (intravenous) | RPMI 1640 (ATCC Catalog No. 30-2001) with 10% Heat inactivated FBS | Puromycin at 2 µg/mL | BW124734 |
Ovarian cancer
| Cell line | Reporter type | Tissue | Applications | Culture media | Antibiotic selection – not required for culturing | Product number |
|---|---|---|---|---|---|---|
| SKOV3-Red-F-luc | Firefly luciferase (luminescence) | Human: adenocarcinoma, ovary | • Subcutaneous tumor models • Peritoneal dissemination models (intraperitoneal injection) |
McCoy's 5a (ATCC Cat. No. 30-2007) + 10% FBS | Puromycin at 2 µg/mL | BW119276 |
Pancreatic cancer
| Cell line | Reporter type | Tissue | Applications | Culture media | Antibiotic selection – not required for culturing | Product number |
|---|---|---|---|---|---|---|
| BxPc-3-Red-F-luc | Firefly luciferase (luminescence) | Human: pancreas adenocarcinoma | • Subcutaneous tumor models • Orthotopic tumor model |
RPMI 1640 (ATCC Catalog No. 30-2001) with 10% Heat inactivated FBS | Puromycin at 2 µg/mL | BW125058 |
Prostate cancer
| Cell line | Reporter type | Tissue | Applications | Culture media | Antibiotic selection – not required for culturing | Product number and tech sheet |
|---|---|---|---|---|---|---|
| LNCaP-Red-F-luc | Firefly luciferase (luminescence) | Human: prostate; adenocarcinoma | • Subcutaneous tumor models • Subcutaneous tumor models with metastasis (SCID-bg mice) • Orthotopic prostate tumor model |
RPMI 1640 (ATCC Catalog No. 30-2001) with 10% UNHEATED FBS | Puromycin at 2 µg/mL | BW125055 |
| PC-3-Red-F-luc | Firefly luciferase (luminescence) | Human: Prostate Cancer | • Experimental metastasis model • Orthotopic prostate cancer models |
Eagle’s MEM ATCC Cat. No. 30-2003 with 10% Heat inactivated FBS (Hyclone) | Puromycin at 2 µg/mL | BW128444 |
| PC-3-Red-F-luc-GFP | Dual: Luciferase (luminescence) and GFP (fluorescence) | Human: Prostate; adeno- carcinoma | • Orthotopic and subcutaneous tumor models • Ex vivo cell isolation using fluorescent activated cell sorter (FACS) • Post genomic analyses of isolated tumor cells • Fluorescent detection of of GFP positive cells using Nuance Multispectral imaging systems |
Eagle’s MEM ATCC Cat. No. 30-2003 with 10% Heat inactivated FBS (Hyclone) | There is NO antibiotic selection for this cell line. | BW133416 |
IVISbrite Lentivirus particles for creating your own bioluminescent cells
View our IVISbrite Lentiviral particles page for products and information on creating your own bioluminescent cells.
Substrates
Please see our page on IVISbrite D-luciferin substrates for more information.
Protocols
- Culture Guidelines
- Cell preparation and imaging procedure – subcutaneous
- Cell preparation and imaging procedure – intravenous
- Cell preparation and imaging procedure – ex vivo
- Examples of validated models and cell injection number
- Imaging Procedure
- Preparation of luciferin for in vitro or in vivo assays
- IVISbrite D-Luciferin Bioluminescent Substrate (formerly RediJect™ D-luciferin) protocol
- IVISbrite D-Luciferin Ultra Bioluminescent Substrate (formerly RediJect D-luciferin Ultra) protocol
For research use only. Not for use in diagnostic procedures. The information provided above is solely for informational and research purposes only. The information does not constitute medical advice and must not be used or interpreted as such. Consult a qualified veterinarian or researcher for specific guidance or use information. Revvity assumes no liability or responsibility for any injuries, losses, or damages resulting from the use or misuse of the provided information, and Revvity assumes no liability for any outcomes resulting from the use or misuse of any recommendations. The information is provided on an "as is" basis without warranties of any kind. Users are responsible for determining the suitability of any recommendations for the user’s particular research. Any recommendations provided by Revvity should not be considered a substitute for a user’s own professional judgment. Users are solely responsible for complying with all relevant laws, regulations, and institutional animal care and use committee (IACUC) guidelines in their use of the information provided.